Sage Therapeutics Announces R&D Leadership Transition
Sage Therapeutics (SAGE) announced a leadership transition as Chief Medical Officer Dr. Laura Gault will depart the company effective March 21, 2025. Dr. Gault, who joined in November 2022, has been responsible for leading the company's product pipeline development across all stages.
Chief Scientific Officer Mike Quirk will temporarily assume key responsibilities, including providing strategic guidance for clinical development programs. The company acknowledged Dr. Gault's contributions, particularly highlighting her advocacy for maternal mental health advancement.
Sage Therapeutics (SAGE) ha annunciato un cambiamento nella leadership, poiché il Chief Medical Officer Dr. Laura Gault lascerà l'azienda a partire dal 21 marzo 2025. La Dr. Gault, che è entrata in azienda nel novembre 2022, è stata responsabile della guida dello sviluppo del pipeline di prodotti dell'azienda in tutte le fasi.
Il Chief Scientific Officer Mike Quirk assumerà temporaneamente responsabilità chiave, inclusa la fornitura di orientamenti strategici per i programmi di sviluppo clinico. L'azienda ha riconosciuto i contributi della Dr. Gault, evidenziando in particolare il suo impegno per il progresso della salute mentale materna.
Sage Therapeutics (SAGE) anunció una transición en el liderazgo, ya que la Directora Médica Dr. Laura Gault dejará la empresa a partir del 21 de marzo de 2025. La Dr. Gault, quien se unió en noviembre de 2022, ha sido responsable de liderar el desarrollo del pipeline de productos de la empresa en todas las etapas.
El Director Científico Mike Quirk asumirá temporalmente responsabilidades clave, incluida la provisión de orientación estratégica para los programas de desarrollo clínico. La empresa reconoció las contribuciones de la Dr. Gault, destacando especialmente su defensa del avance en la salud mental materna.
Sage Therapeutics (SAGE)는 리더십 전환을 발표했으며, 최고 의학 책임자 Dr. Laura Gault가 2025년 3월 21일부로 회사를 떠납니다. Gault 박사는 2022년 11월에 합류하여 회사의 제품 파이프라인 개발을 모든 단계에서 이끌어 왔습니다.
최고 과학 책임자 Mike Quirk가 임시로 주요 책임을 맡아 임상 개발 프로그램에 대한 전략적 지침을 제공할 것입니다. 회사는 Gault 박사의 기여를 인정하며, 특히 모성 정신 건강 증진을 위한 그녀의 옹호를 강조했습니다.
Sage Therapeutics (SAGE) a annoncé une transition de leadership, puisque le Directeur Médical Dr. Laura Gault quittera l'entreprise à compter du 21 mars 2025. Le Dr Gault, qui a rejoint l'entreprise en novembre 2022, a été responsable de la direction du développement du pipeline de produits de l'entreprise à tous les stades.
Le Directeur Scientifique Mike Quirk assumera temporairement des responsabilités clés, y compris la fourniture de conseils stratégiques pour les programmes de développement clinique. L'entreprise a reconnu les contributions du Dr Gault, soulignant en particulier son plaidoyer en faveur de l'avancement de la santé mentale maternelle.
Sage Therapeutics (SAGE) gab einen Führungswechsel bekannt, da die Chief Medical Officer Dr. Laura Gault das Unternehmen zum 21. März 2025 verlassen wird. Dr. Gault, die im November 2022 zum Unternehmen kam, war verantwortlich für die Leitung der Produktpipeline-Entwicklung in allen Phasen.
Der Chief Scientific Officer Mike Quirk wird vorübergehend wichtige Aufgaben übernehmen, einschließlich der Bereitstellung strategischer Leitlinien für klinische Entwicklungsprogramme. Das Unternehmen erkannte die Beiträge von Dr. Gault an und hob insbesondere ihr Engagement für den Fortschritt der psychischen Gesundheit von Müttern hervor.
- Smooth transition plan with internal executive (CSO) assuming responsibilities
- Departure of key executive (CMO) creating leadership gap
- Interim leadership arrangement suggests potential disruption in clinical development oversight
“I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions,” said Barry Greene, Chief Executive Officer of Sage Therapeutics. “Laura has been a relentless advocate for progress in maternal mental health, and we are deeply appreciative of all her contributions and wish her continued success in the future.”
About Sage Therapeutics
Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304999395/en/
Investor Contact
Ashley Kaplowitz
Ashley.Kaplowitz@sagerx.com
Media Contact
Francesca Dellelci
Francesca.Dellelci@sagerx.com
Source: Sage Therapeutics, Inc.
FAQ
When is Dr. Laura Gault leaving her position as CMO at Sage Therapeutics (SAGE)?
Who will take over Dr. Gault's responsibilities at SAGE after her departure?
How long did Dr. Laura Gault serve as Chief Medical Officer at SAGE?
What were Dr. Gault's main responsibilities at Sage Therapeutics (SAGE)?
